Skip to main content
. 2023 Jan 18;32(1):49–60. doi: 10.1159/000529202

Fig. 2.

Fig. 2

Nomogram for predicting 1-, 3-, and 5-year OS (a) and CSS (b) for stage II–IV LCLC, and the ROC curve of validation cohort for predicting 1-, 3-, and 5-year OS (c) and CSS (d). OS, overall survival; CSS, cancer-specific survival; LCLC, large-cell lung carcinoma; ROC, receiver operating characteristic. *p <0.05, **p <0.01, ***p <0.001.